News - Full Story

Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer

MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife^® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy - supporting the system's versatility and value to medical care teams.

"An extensive number of peer-reviewed scientific manuscripts have been published reporting on CyberKnife prostate SBRT efficacy and tolerability. This most recent RSS data demonstrates the ongoing interest in advancing patient care with the system, based on its ability to deliver the precision and accuracy necessary to not just help men to survive prostate cancer but also to have a meaningful quality of life post treatment," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.

The CyberKnife System enables treatment of prostate cancer using a form of radiation therapy called stereotactic body radiation therapy (SBRT) - very precise, high doses of radiation are delivered over a shorter duration than traditional treatments. The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT.

CyberKnife Platform for Prostate Cancer: The CyberKnife platform offers an effective treatment option for prostate tumors in 4-5 sessions, compared to conventional radiation therapy that usually requires approximately 30-40 sessions over 8-10 weeks. Data presented at the RSS meeting showed its ability to:

Effectively treat high-risk disease while preserving quality of life. Study authors concluded, "At the 3-year follow-up mark, favorable biochemical control was achieved, and patients had largely recovered to near baseline urinary and bowel function . . . These findings underscore the potential of SBRT as a convenient treatment option for high-risk prostate cancer, offering promising outcomes and preserving patient quality of life¹."
Provide a viable option with "a low incidence of short-term genitourinary (GU) and gastrointestinal (GI) toxicities" for reirradiation of locally recurrent prostate cancer².

The prostate gland can move unpredictably throughout the course of treatment. In fact, the prostate has been documented to move as much as 10 mm in as little as 30 seconds due to normal patient bodily functions - such as filling of the bladder, gas in the bowel, or even slight patient movement during the procedure^3,4,5,6,making the ability to track, detect and correct for motion critically important.

The CyberKnife System, using advanced imaging and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery, with the Accuray proprietary Synchrony^® technology, can track the tumor and continually verify its position, automatically correcting and adapting the radiation beam position for even the slightest movement. For example, if the prostate moves during treatment the CyberKnife^® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases-while making commonly treatable cases even easier-to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations related to the ability of our systems to be an effective treatment option, patient experiences and patient outcomes. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 7, 2024, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

¹ "Health-Related Quality of Life Following Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer." Presenting author Vaibhav Sharma, M.D., Resident Physician, Georgetown University Hospital, Washington, DC, USA.
² "Acute Toxicity Following PSMA-Directed Focal Salvage Robotic SBRT for Local Recurrences Following Prior Robotic Prostate SBRT." Presenting author Zachary Wilson, Medical Student, Georgetown University Hospital, Washington, DC, USA.
³ Drexler and Furweger. "Quality assurance of a robotic, image guided radiosurgery system." WC 2009, IFMBE Proceedings 25/I, 492-495, 2009. https://link.springer.com/chapter/10.1007/978-3-642-03474-9_138.
⁴ Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR. The CyberKnife® Robotic Radiosurgery System in 2010. Technology in Cancer Research & Treatment. 2010;9(5):433-452. doi:10.1177/153303461000900502.
⁵ Yu C, Main W, Taylor D, Kuduvalli G, Apuzzo ML, Adler JR Jr. An anthropomorphic phantom study of the accuracy of Cyberknife spinal radiosurgery. Neurosurgery. 2004 Nov;55(5):1138-49. doi: 10.1227/01.neu.0000141080.54647.11. PMID: 15509320.
⁶ Antypas C, Pantelis E. Performance evaluation of a CyberKnife G4 image-guided robotic stereotactic radiosurgery system. Phys Med Biol. 2008 Sep 7;53(17):4697-718. doi: 10.1088/0031-9155/53/17/016. Epub 2008 Aug 11. PMID: 18695294.

Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-be-effectively-treated-in-5-days-using-the-accuray-cyberknife-system-302099017.html

SOURCE Accuray Incorporated